Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has acted for Bergs Timber in connection with its acquisition of Fågelfors Hyvleri and refinancing
Mandate

Vinge has acted for Bergs Timber in connection with its acquisition of Fågelfors Hyvleri and refinancing

July 02, 2019 Capital Markets and Public M&A

Vinge has acted for Bergs Timber in connection with its acquisition of all shares in AB Fågelfors Hyvleri, a company with wood pellet production located in Fågelfors, Sweden. 

The purchase price amounts to SEK 48 million, of which SEK 30 million is paid in cash and SEK 18 million is paid in 5,940,594 newly issued class B shares in Bergs Timber. Bergs Timber has also, in connection with the acquisition, made a refinancing of outstanding credit facilities. 

Vinge’s team mainly comprised Jesper Schönbeck, Ulrich Ziche, Sofia Törnroth Nyberg, Astrid Isberg, Stina Bengtsson, Axel Jansson, Pauline Lagerstrand and Viktoria Owetz.

Related

Vinge has advised Hansa Biopharma in connection with entering into a financing agreement

 Vinge has advised Hansa Biopharma AB (publ), a commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions, listed on Nasdaq Stockholm, in connection with a U.S. convertible note purchase agreement comprising USD 30 million aggregate principal amount of unsecured convertible senior notes.
March 23, 2026

Vinge advises in connection with data center provider EcoDataCenter’s tap issue of SEK 500 million bonds

 Vinge has advised in connection with EcoDC Holding AB (publ)'s tap issue of SEK 500 million senior unsecured bonds under the existing framework of up to SEK 2 billion.
March 19, 2026

Vinge has advised Cinclus Pharma in connection with entering into financing agreement

 Vinge has advised Cinclus Pharma Holding AB (publ), a late-stage clinical pharmaceutical company developing next-generation treatments for gastric acid-related diseases listed on Nasdaq Stockholm, in connection with a long-term structured credit agreement for a total of up to EUR 28 million divided into four tranches, of which two are convertibles.
March 16, 2026